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95% CI, 35.85 to 2.44; P¼ 0.025). Results were consistent when
we analyzed using intention-to-treat and per protocol principles. There
were no differences in fluid status, peritoneal ultrafiltration, and
peritoneal transport between groups during follow-up.
This study clearly showed that icodextrin solution preserves residual
urine volume better than glucose solution.
(Medicine 95(13):e2991)
Abbreviations: ANP = atrial natriuretic peptide, CI = confidence
interval, ESRD = end-stage renal disease, GFR = glomerular
filtration rate, ITT = intention-to-treat, IVC = inferior vena cava,
PD = peritoneal dialysis, RRF = residual renal function.
INTRODUCTION
P eritoneal dialysis (PD) has been established as an effectivedialysis treatment in end-stage renal disease (ESRD), and
approximately 200,000 patients worldwide are maintained on
PD.1 However, many researchers have much concern about the
deleterious effects of the high glucose content of PD solutions
on the peritoneal membrane overtime.2 Therefore, there was
growing need for the development of new solutions designed to
minimize glucose-induced toxicity, and thus PD solutions
containing low glucose degradation products or an alternative
osmotic agent to glucose, such as icodextrin and amino-acids,
have been developed. Icodextrin is a mixture of high molecular
weight, water-soluble glucose polymers isolated by the frac-
tionation of hydrolyzed cornstarch.3 Although diffusion across
the peritoneal capillary is the principal mechanism for glucose
absorption from the peritoneal cavity, icodextrin mainly is
absorbed by convective fluid movement out of the peritoneal
cavity via the lymphatic system.4 This results in relatively
constant osmotic pressure, which can provide sustained ultra-
filtration during the long dwell time.
A number of studies have reported that icodextrin-based
solution provides various clinical benefits compared to con-
ventional glucose-based solutions.5,6 Indeed, icodextrin
solution is particularly helpful and has been widely used to
treat fluid overload in PD patients.7–14 However, whether
icodextrin can preserve residual renal function (RRF) remains
controversial. Icodetextrin solution has the merit of sustained
ultrafiltration, but this can have harmful impact on RRF as
excessive ultrafiltration may induce underhydration, leading to
a faster decline in RRF. Konings et al15 first raised this concern
and found a greater reduction in residual glomerular filtration
rate (GFR) in patients using icodextrin than in those using
www.md-journal.com | 1
glucose solutions. In addition, Paniagua et al11 demonstrated
similar effects of icodextrin on residual GFR in high and high-
average transport PD patients with diabetes. In contrast, favor-
able effects of icodextrin on RRF have also been reported. A
previous study by Davies et al7 observed that icodextrin better
preserved urine volume compared to a glucose-based solution
during 6 months, and another recent study found that a com-
bination of 3 biocompatible PD solutions including icodextrin
better preserved urine volume during 12 months.16 These all
findings indicate that RRF can be preserved by icodextrin. On
the other hand, several randomized controlled trials reported
neutral effects of icodextrin on RRF evidenced by a similar
decline in renal creatinine clearance or urine volume by ico-
dextrin and glucose-based solution.12,17–19 These conflicting
results regarding the effect of icodextrin on RRF can be
attributable to differences in study design, baseline volume
status, and other unknown factors that can affect RRF during
the study period. Most studies have limitations in RRF being
defined as a secondary outcome, insufficient statistical power,
relatively short observation period, or small sample size. Above
all, we speculate that treatment-associated changes in volume
status might differ depending on different concentrations of
comparative glucose solution, thus resulting in conflicting
findings. In fact, in the study by Konings et al,15 the glucose
solution had a concentration of 1.36%, whereas the solution
used by Davies et al7 had a concentration of 2.27%.
However, given the strong relationship between adequate
ultrafiltration or RRF and clinical outcomes in PD patients, we
believe that a more judicious approach is warranted, with
particularly strict attention to fluid status. With this background
Chang et alin mind, we conducted this study to investigate whether ico-
dextrin solution can better preserve RRF in PD patients com-
pared to conventional glucose-based solutions.
METHODS
Patients and Study Design
This multicenter prospective randomized controlled
open-label trial was undertaken from October 2010 to June
2014 at 8 centers in Korea (Clinicaltrials. gov registration
NCT01170858). This study was carried out in accordance with
the Declaration of Helsinki and approved by the Institutional
Review Boards of all participating hospitals. Written
informed consent was obtained from all participants before
enrollment.
Adult PD patients (aged 20 years) with ESRD who were
maintained on PD with the Baxter ultrabag system and had
a measured urine volume 750mL/day at enrollment were
eligible for the study. Patients who had a life expectancy of
<12 months, had been on hemodialysis or received a kidney
transplant before the initiation of PD, had been on automated
PD, had been treated with icodextrin solution before enrollment,
had poor medical conditions that interfered with their ability to
comply with the study protocol, and had known or suspected
allergies to the trial product were excluded from the study.
Patients who were suspected of having uncontrolled volume
status requiring the repeated use of 4.25% glucose PD solutions
in addition to 2.5% glucose solution or icodextrin, or volume
depletion or hypotension caused by 2.5% glucose PD solution or
icodextrin solution was also excluded from the study. During the
recruitment period of October 2010 to May 2013, 205 patients
fulfilled the inclusion criteria; 100 patients consented to partici-
pate in the study.
2 | www.md-journal.comAfter a 4-week screening period, 100 patients were ran-
domly assigned to receive either 1 exchange of icodextrin
solution (Extraneal, Baxter Healthcare Ltd., Singapore; icodex-
trin group) for 8 hour-dwell time and 2 exchanges of 1.5%
glucose-based biocompatible neutral pH solution (Physioneal,
Baxter Healthcare Ltd., Singapore) or 1 exchange of2.5% and
2 exchanges of 1.5% glucose-based biocompatible solutions
(Physioneal, Baxter Healthcare Ltd., Singapore; control group).
To ensure adequate allocation concealment, the randomization
was performed centrally using a web-based system and strati-
fied according to diabetic nephropathy and center. The sub-
sequent escalation in the number of continuous ambulatory PD
exchanges and the additional use of glucose solution were
permitted in both groups to achieve adequate control of small
solute clearance or ultrafiltration. However, patients were
excluded if they had to use 2 or more exchanges of 4.25%
high concentration glucose solutions per day to control volume
overload.
Clinical Follow-Up and Data Collection
Demographic and clinical data were collected at enroll-
ment and included age, gender, cause of ESRD, comorbidities,
and center size. The Charlson comorbidity index was used to
compare the comorbid conditions at baseline.20 Two centers that
had fewer than 40 PD patients were considered ‘‘less experi-
enced center.’’ The clinic visits were scheduled every 3 months,
and clinical and laboratory data were obtained at each visit.
These included body weight, blood pressure, serum hemo-
globin, albumin, osmolality, sodium, fasting glucose, HbA1c,
total cholesterol, low-density lipoprotein, triglycerides, high-
sensitive C-reactive protein, prescribed dialysate volume and
dialysate glucose exposure, and medications. During each visit,
all adverse reactions were also recorded.
Residual GFR and fluid status were assessed at baseline
and at 6 and 12 months. Residual GFR was calculated as
the average urea and creatinine clearance from a 24-hour urine
collection.21 To assess fluid status, we used 3 different assess-
ment tools: echocardiography for left atrial volume index, left
ventricular end diastolic diameter, and inferior vena cava (IVC)
collapsibility index; measurement of plasma atrial natriuretic
peptide (ANP) levels; and whole-body multifrequency bioelec-
trical impedance analysis (Fresenius Medical Care, Germany).
Plasma ANP level was measured using an enzyme-linked
immunosorbent assay kit (Abcam, Cambridge, UK) according
to the manufacturer’s protocol. IVC collapsibility index was
calculated as (maximal diameter on expirationminimal
diameter on deep inspiration)/maximal diameter on
expiration 100. All patients were followed for 12 months.
Each assessment was performed by a single observer who was
blinded to patient information and treatment allocations.
Study Outcomes
The primary outcomewas the change in RRF including the
slope of the decline in residual GFR and daily urine volume over
12 months. The secondary outcome was the change in fluid
status during the study period.
Power Calculation
At least 50 subjects were required for each group in order
to detect a 50% difference in residual GFR and urine volume
Medicine  Volume 95, Number 13, April 2016over 12 months between groups, if the type I error rate was 5%
and the type II error was 20% given a 30% drop-out rate during
the study period.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
Statistical Analysis
All values are expressed as mean standard deviations or
percentages. Statistical analyses were performed using SAS
version 9.2.3 (SAS, Institute Inc., Cary, NC) and R version 3.0.2
(http://cran.r-project.org/). The data were compared using Stu-
dent’s t-test and the Chi-square test. The Kolmogorov–Smirnov
test was used to determine the normality of the parameters
distributions. If the data did not show a normal distribution, they
were expressed as the median and interquartile range (or after
log-transformation) and were compared using the Mann–Whit-
ney U-test or the Kruskal–Wallis test.
We primarily analyzed data on an intention-to-treat (ITT)
basis. Additional per-protocol analysis was also performed on
patients who completed the entire trial according to the protocol.
For the primary outcome of change in RRF, the slope of the
decline in residual GFR (mL/min/month/1.73m2) and daily urine
volume (mL per month) over 12 months were calculated and
compared using generalized linear mixed models for repeated
measures, and expressed as the estimate coefficient and 95%
confidence interval (CI). No confounding baseline variables were
found, and no additional covariates were therefore added to the
model. For the secondary efficacy endpoints, mean changes in
fluid status parameters from baseline to 6 and 12 months were
summarized for each treatment group, and comparisons between
groups were also made based on the generalized linear mixed
model. In each case, the generalized linear mixed model incorp-
orated time (corresponding to those visits when the endpoint of
interest was measured), treatment group (icodextrin vs glucose-
based solution), and interaction (time-by-treatment group) as the
primary independent class variables. A P-value of 0.05 was
considered statistically significant.
RESULTS
Medicine  Volume 95, Number 13, April 2016Patient Characteristics
Between September 2010 and May 2013, a total of 100
patients were randomized to receive either icodextrin-containing
FIGURE 1. Enrollment, randomization, and follow-up of study partic
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(n¼ 49) or glucose (n¼ 51, control) solution (Figure 1). The 2
groups were well balanced for all baseline characteristics
(Table 1).
Decrease in Residual Renal Function
We performed both ITT primary efficacy analysis (n¼ 97)
and per-protocol analysis (n¼ 81) to evaluate the decrease in
RRF between groups in terms of the slope of residual GFR
decline (Figure 2) and daily urine volume (Figure 3) at 1 year.
During the 1 year of therapy, in the ITT population, the mean
slope of decrease in residual GFR was 0.170mL/min/month/
1.73m2 in the icodextrin group and 0.155mL/min/month/
1.73m2 in the control group (95% CI, 0.06 to 0.10;
P¼ 0.701). When the curvature of the GFR decline was mod-
eled by analyzing log-transformed data, the log scale trends in
the icodextrin and control groups were0.042 and0.042mL/
min/month/1.73m2, respectively (95% CI, 0.02 to 0.02;
P¼ 0.994). In the per-protocol population, the differences in
decreases of residual GFR between treatments over the entire
study period were not statistically significant (0.149 in the
icodextrin group vs 0.153mL/min/1.73m2 per month in the
control group, respectively; 95% CI, 0.08 to 0.08; P¼ 0.920).
In contrast, daily urine volume declined faster in the
control group than in the icodextrin group (31.02 vs
11.88mL per month [95% CI, 35.85 to 2.44;
P¼ 0.025] in the ITT population and 31.96 vs 12.12mL
per month [95% CI, 32.67 to 2.61; P¼ 0.024] in the per-
protocol population, respectively). Notably, these significant
differences in the slope of daily urine volume decline between
groups were more profound in the models using log-trans-
formed data (P¼ 0.010 in the ITT and P¼ 0.007 in the per-
protocol population, respectively). Furthermore, we created
several multivariable models adjusted for clinical factors,
underlying kidney diseases, high-sensitive C-reactive protein,
Effect of Icodextrin on RRFvolume parameters, and medications such as angiotensin recep-
tor blockers, nonsteroidal antiinflammatory drugs, and diure-
tics. These rigorous adjustment models consistently revealed
ipants. PD¼peritoneal dialysis, RRF¼ residual renal function.
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TABLE 1. Baseline Characteristics of the Study Participants
Control Group (n¼ 51) Icodextrin Group (n¼ 49) P
Age, years 55.2  13.0 52.1 11.6 0.216
Gender (male) 29 (56.9) 30 (61.2) 0.658
Incident patients 36 (70.6) 31 (63.3) 0.436
Dialysis vintage in prevalent patients, months 10.3 [5.8–14.6] 15.2 [8.5–31.5] 0.204
Body mass index, kg/m2 23.6  3.8 24.5 3.9 0.258
Diabetes 30 (58.8) 27 (55.1) 0.707
Charlson comorbidity index score 5.3  2.7 4.8 2.6 0.297
Patients treated in less experienced center 4 (7.8) 4 (8.2) 0.953
Systolic blood pressure, mmHg 137.0  17.9 129.9 18.4 0.054
Diastolic blood pressure, mmHg 81.0  10.9 77.8 11.6 0.159
Laboratory findings
Hemoglobin, g/dL 11.1  1.5 11.4 1.4 0.476
Albumin, g/dL 3.3  0.5 3.3 0.5 0.974
Serum osmolality, mOsm/kg 304.7  7.8 306.1 8.2 0.438
Fasting serum glucose, mg/dL 103 [88–172] 107 [88–173] 0.966
HbA1c, % 6.7  1.5 6.7 1.5 0.950
Atrial natriuretic peptide, pg/mL 360 [21–676] 305 [70–843] 0.671
24-hour urine volume, mL/day 1443  620 1400 590 0.727
Residual GFR, mL/min/1.73 m2 6.0  3.3 6.3 3.3 0.611
Echocardiographic parameters
LA volume index, mL/m2 28.9  10.0 30.6 15.1 0.491
LV end-diastolic diameter, mm 50.2  5.1 51.1 6.6 0.449
LV mass index, g/m2 114.3  32.3 123.6 48.7 0.271
TR peak velocity, m/sec 2.3  0.4 2.4 0.4 0.222
IVC collapsibility index, % 43.9  21.4 44.8 18.0 0.865
Body composition
TBW, L 34.23  6.91 34.18 6.44 0.976
ECF, L 16.75  3.48 16.44 3.40 0.667
ECW/TBW ratio 0.49  0.04 0.48  0.04 0.538
Dialysis parameters
D/P cr at 4 hours 0.72  0.09 0.72 0.09 0.845
Total Kt/V urea 2.37  0.66 2.52 0.71 0.293
Prescribed dialysate volume, L/day 6.2  0.7 6.3 0.8 0.731
Peritoneal ultrafiltration, mL/day 270 [338–750] 417 [87–800] 0.390
Medications
Angiotensin receptor blockers 39 (76.5) 35 (71.4) 0.566
Diuretics 42 (82.4) 36 (73.5) 0.483
Nonsteroidal antiinflammatory drugs 3 (5.9) 4 (8.2) 0.712
Dose of furosemide, mg/day 80 [40–80] 80 [0–80] 0.685
Values for categorical variables are given as a number (percentage); values for continuous variables are given as mean standard deviation or
median [interquartile range]. D/P cr¼ dialysate/plasma creatinine ratio, ECW¼ extracellular water, GFR¼ glomerular filtration rate, LA¼ left atrial,
atio
Chang et al Medicine  Volume 95, Number 13, April 2016significantly faster decreases in residual urine volume in the
control group than in the icodextrin group (data not shown). In a
post-hoc analysis, no relationship between these treatment
differences with respect to urine volume and the use of diuretics
including furosemide dosage was found.
Secondary Outcomes
Linear mixed models with repeated measures revealed no
differences between treatment groups for most of the secondary
endpoints. Not surprizingly, the use of 2.5% glucose solution
resulted in higher exposure to glucose than icodextrin solution
LV¼ left ventricular, TBW¼ total body water, TR¼ tricuspid regurgitthroughout the study (Table 2). Fluid status was thoroughly
evaluated using 3 different methods: echocardiography, body
composition measured by bioelectrical impedance analysis, and
4 | www.md-journal.complasma ANP concentrations. Overall, these parameters in the 2
groups were comparable at all-time points (Figure 4). Similarly,
peritoneal ultrafiltration and peritoneal membrane transport did
not differ between groups during follow-up. Other clinical and
laboratory findings and the use of medications such as angio-
tensin receptor blockers and diuretics were also similar between
groups throughout the study.
Adverse Events
Seventy-nine percent (n¼ 79) of patients experienced at
least 1 adverse events. The number of patients who experienced
n.an adverse event and the overall number of adverse events was
similar between the 2 groups. All adverse events are shown in
Table 3, and the rates were not significantly different between
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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d s
Medicine  Volume 95, Number 13, April 2016 Effect of Icodextrin on RRFgroups. Peripheral edema occurred in 28 (19%) and 20 (13%)
patients in the control and icodextrin group, respectively
(P¼NS), which disappeared after replacing 1.5% glucose
solution with 1 exchange of 2.5% or 4.25% glucose solution
FIGURE 2. Changes in residual glomerular filtration rates overtim
analysis. Gray lines represent individual patient measurements, anfor several days. Two patients in the control group dropped out
during the study because they used 2 or more exchanges of
4.25% glucose solution per day to manage volume overload.
DISCUSSION
In this study, we aimed to evaluate the effect of icodextrin
solution on the preservation of RRF in PD patients compared to
glucose solutions. We showed that icodextrin solution attenu-
ated the rate of decline in daily urine volume compared to the
controls, but did not affect residual GFR. These findings were
consistently reproduced in the ITT and per-protocol popu-
lations, and even when using rigorously adjusted multivariable
models. Our robust findings suggest that icodextrin is a prom-
ising dialysis solution for achieving important therapeutic goals,
such as the preservation of residual urine volume and fluid
management in PD patients.
Fluid overload has long been considered a therapeutic
target in patients undergoing dialysis22 because it is associated
FIGURE 3. Changes in daily urine volume over time between groups.
represent individual patient measurements, and solid and dash lines
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.with adverse outcomes such as hypertension, left ventricular
hypertrophy, congestive heart failure,23–27 and even malnu-
trition–inflammation complex syndrome.28,29 For these
reasons, there has been a tremendous demand to adequately
maintain euvolemia to improve clinical outcomes in these
patients. To this end, multidisciplinary approach has been
suggested, including sodium and water restriction, preservation
of RRF, diuretic use, and preservation of peritoneal membrane
function.30 In particular, the preservation of RRF is of para-
mount importance in achieving this goal because loss of kidney
function can predict morbidity and mortality.31,32 Interestingly,
among the many methods introduced to date, recent trials have
shown that the use of biocompatible PD solution itself can
preserve RRF.33–35 However, these studies had limitations,
including less peritoneal ultrafiltration induced by biocompa-
tible solutions than by glucose-based solutions, and this raised
concerns about fluid management. Icodextrin solution has been
highlighted as an alternative solution to improve fluid status by
increasing peritoneal ultrafiltation.8,11,36–39 Nevertheless, there
are many controversial observations regarding whether RRF
between groups. (A) intention-to-treat analysis, (B) per-protocol
olid and dash lines represent predicted slopes.can be preserved by icodextrin.7,11,12,15,17,19 Most of these
studies analyzed RRF as a secondary outcome and were limited
by insufficient assessment of fluid status and a lack of statistical
(A) intention-to-treat analysis, (B) per-protocol analysis. Gray lines
represent predicted slopes.
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Medicine  Volume 95, Number 13, April 2016 Effect of Icodextrin on RRFpower. Moreover, there is a growing concern about faster
decline of RRF by icodextrin-induced higher ultrafiltration
compared to glucose solution.11,15,40 Our randomized con-
trolled study addressed this issue and clearly demonstrated that
icodextrin solution preserves RRF better than glucose solutions.
This finding is unlikely to be explained by escalation of high
concentration glucose solution or the use of diuretics because
glucose exposure did not change in the control group throughout
the study and the use of medications that could potentially affect
urine volume was comparable between groups.
RRF is generally evaluated by assessing both residual GFR
and urine volume. We showed that urine volume was preserved
by icodextrin, while residual GFR was not. However, residual
GFR is a numerical assessment of small solute clearance and
may not represent true kidney function. In fact, Bargman et al41
reanalyzed the Canada–USA (CANUSA) study and found that
residual urine volume was more important than residual GFR in
predicting adverse outcomes. In accordance with our findings,
previous studies have shown that treatment regimens including
icodextrin preserved urine volume but not residual GFR.7,16,19
These findings suggest that residual urine volume has important
implications beyond GFR from a clinical viewpoint.
FIGURE 4. Changes in fluid status such as left ventricular end-diasto
water/total body water ratio (C), and plasma atrial natriuretic pept
water, LVEDD¼ left ventricular end-diastolic diameter, IVC¼ inferDaily use of long-dwell of icodextrin has been reported to
improve fluid status.7,11 However, our study did not demon-
strate benefits of icodextrin on overall fluid status despite a
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.significant preservation of urine volume in the icodextrin group.
Of note, the control group had median urine volume>1000mL/
day at enrollment, and this was maintained relatively well until
the end of the study although residual urine volume declined
faster than in the icodextrin group. This can be partly explained
by the use of biocompatible solutions in both the control and
icodextrin groups. Several randomized controlled trials have
shown that biocompatible solutions can preserve RRF better
than conventional glucose solutions.33–35 In addition, it is
possible that reciprocal increased peritoneal ultrafiltration
caused by high concentration glucose solutions might compen-
sate for a decrease in urine volume to maintain fluid status.42 In
fact, there have been discrepant findings in residual urine
volume depending on peritoneal ultrafiltration as seen in the
studies by Davies et al7 and Konings et al.15 To overcome this
issue, in our study, the control group used 2.5% glucose solution
to induce peritoneal ultrafiltration similar to icodextrin solution.
It should be noted that icodextrin preserved urine volume better
than glucose solution, while maintaining peritoneal ultrafiltra-
tion comparable to the high concentration glucose solution.
When we calculated total ultrafiltration volume as a sum of
urine volume and peritoneal ultrafiltration, there was a slightly
iameter (A), inferior vena cava collapsibility index (B), extracellular
concentrations (D) overtime between groups. ECW¼extracellular
ena cava, TBW¼ total body water.higher total ultrafiltration in the icodextrin group than in the
control group by approximately 200mL/day (data not shown).
This small difference may not be adequately reflected in overall
www.md-journal.com | 7
TABLE 3. Adverse Events by Treatment Group
Control Group (n¼ 51) Icodextrin Group (n¼ 49)
Cardiovascular
Ischemic heart disease 1 (1) 4 (4)
Edema/fluid overload 28 (19) 20 (13)
Hypertension 14 (13) 9 (9)
Hypotension/dehydration 3 (3) 0
Heart failure 1 (1) 0
Dyspnea 5 (4) 3 (3)
Cardiac arrest/death 0 1 (1)
Infectious
Peritonitis 9 (9) 10 (10)
Exit site infection 10 (6) 15 (12)
Respiratory/cough 10 (5) 8 (9)
Gastrointestinal
Abdominal pain/discomfort 3 (3) 1 (1)
Nausea/vomiting 6 (6) 8 (6)
Constipation 2 (2) 3 (2)
Diarrhea 5 (5) 4 (4)
Fatigue/general weakness 8 (8) 10 (7)
Endocrine
Hyperglycemia 4 (4) 3 (3)
Hypoglycemia 2 (2) 0
Neuromuscular/musculoskeletal
Peripheral neuropathy/muscle cramp 2 (2) 3 (3)
Dizziness 10 (6) 9 (8)
Headache 6 (5) 4 (3)
Skin
Pruritus 4 (3) 3 (3)
Rash/urticaria 2 (1) 1 (1)
Hernia 0 3 (3)
Peritoneal leak 0 1 (1)
Other 6 (5) 4 (3)
Total number of any adverse events 139 (40) 125 (39)
ienc
Chang et al Medicine  Volume 95, Number 13, April 2016changes of fluid status measured by the current methods used in
this study. Nevertheless, we thoroughly evaluated fluid status
using 3 different assessment tools and found that overall fluid
balance was similar between groups. If icodextrin solution
preserves residual urine volume and maintains adequate per-
itoneal ultrafiltration for a longer period, we should expect more
favorable volume control in patients using icodextrin. Further
long-term investigation is required to detect difference in fluid
status parameters in patients receiving icodextrin compared to
glucose solution.
The mechanism through which icodextrin preserves RRF
is unclear. Davies et al43 showed that plasma ANP levels were
not significantly changed in the icodextrin group, whereas ANP
levels decreased much more in the control group. This finding
raised the potential possibility that icodextrin metabolites can
increase oncotic pressure and hence maintain intravascular
volume by shifting water from other compartments, while
significantly reducing extracellular fluid volume. Such assump-
tion was partly supported by our findings that ANP levels and
IVC collapsibility index were relatively well maintained in the
Total number of serious adverse events
Values are given as a number of events (a number of patients expericodextrin group compared to the glucose solution group
although the differences in the changes of these parameters
were not statistically significant. However, ANP is excreted by
8 | www.md-journal.comthe kidney and ANP levels are not correlated with acute changes
in fluid status in patients with impaired kidney function.
Measurement of IVC collapsibility index is an operator-depen-
dent technique and also limited by interpatient variability.
Unfortunately, there is no good single parameter to represent
intravascular volume. Given the wide variability in the
measurement of ANP levels and IVC collapsibility index and
a lack of evidence for these parameters as valid biomarkers to
assess intravascular volume in dialysis patients, other reliable
markers should be developed in the future and used for the
assessment of fluid status in clinical practice.
Our study has several limitations. First, fluid status was not
directly measured by dilutional methods using deuterium or
sodium bromide. Although the use of deuterium and sodium
bromide is highly reproducible and accurate, these methods are
very costly and cumbersome, and therefore not commonly used
in clinical practice. Instead, we thoroughly evaluated fluid
status using 3 different assessment tools besides clinical assess-
ment and collected longitudinal data. This made our findings
more reliable and provided better interpretation of the changes
19 (18) 18 (17)
ing an event).in fluid status. Second, the decline in residual GFR, a major
primary endpoint, was not significantly different between the
2 groups. We calculated the sample size based on both residual
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
GFR and urine volume to detect a 50% difference in these
parameters over 12 months in the icodextrin group versus the
glucose solution group. Contrary to our expectation, residual
GFR did not differ by 50% between groups, whereas urine
volume did at the end of the study. It should be mentioned that
residual GFR is simply calculated based on creatinine and blood
urea nitrogen levels and such small solute clearance may not tell
true RRF as aforementioned. Third, we did not measure sodium
concentration in the dialysate fluids, thus sodium removal by
icodextrin was not evaluated. Adding icodextrin solution in
patients undergoing automated PD can result in sustained
sodium loss and ultrafiltration via the periteoneum17,44 although
sodium removal capacity is similar between icodextrin and
conventional glucose solutions.7,45 Nevertheless, RRF contrib-
utes to sodium removal and fluid control more than the per-
itoneum, thus it is very inspiring that the use of icodextrin can
maximize sodium removal by enhancing urinary and peritoneal
sodium loss. Finally, as this is an open-label trial, treatment
solutions were not blinded to physicians and patients. However,
randomization was successful and there were no significant
differences in baseline characteristics between groups. To
minimize biased results caused by the study design, RRF,
peritoneal ultrafiltration, fluid status, and other laboratory
parameters were evaluated by observers who were blinded to
detailed information regarding treatment allocation.
In conclusion, this prospective randomized trial showed
that icodextrin solution preserves residual urine volume better
than glucose solution. However, overall fluid status was not
significantly changed during the 1-year study period. Further
Medicine  Volume 95, Number 13, April 2016long-term studies are required to evaluate whether icodextrin
solution improves fluid status, and therefore, provides a
beneficial clinical effect in patients undergoing PD.
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